This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
-
University of Southern California, Los Angeles, California, United States, 90033
Valkyrie Clinical Trials, Los Angeles, California, United States, 90067
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
Stanford University, Palo Alto, California, United States, 94304
START Midwest, Grand Rapids, Michigan, United States, 49546
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States, 89169
Memorial Sloan Kettering Cancer Center- Monmouth, Middletown, New Jersey, United States, 07748
Memorial Sloan Kettering Cancer Center- Commack, Commack, New York, United States, 11725
Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States, 10604
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care, New York, New York, United States, 11101
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Effector Therapeutics,
Douglas Warner, MD, STUDY_DIRECTOR, EFFECTOR Therapeutics, Inc.
2025-03-31